Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Pipeline and Commercial Insight - Schizophrenia - Second generation depots protect market value (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 16/10/2008
- Report Title: Pipeline and Commercial Insight - Schizophrenia - Second generation depots protect market value
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 277
Introduction
Schizophrenia is a chronic and severe mental health disorder affecting around 4.6 million schizophrenia sufferers across the seven major markets. Currently led by oral branded atypical antipsychotics, the schizophrenia market will undergo some big changes over the period 20082017. Prospective players can expect to face stiff competition from generic versions of all currently branded drugs.
Scope
*Analysis of key marketed brands and late-stage pipeline drugs.
*Schizophrenia-specific drug sales volume and value forecasts to 2017 in the US, Japan, and five major European markets.
*Identification of future market events that are expected to affect schizophrenia drug revenues.
*Analysis of patient potential, unmet needs and clinical trial design in schizophrenia.
Highlights
The schizophrenia market is anticipated to grow slowly until 2011 to reach $4.3 billion across the 7MM. Despite the launch of a few pipeline drugs, the market will decline thereafter owing to the widespread launch of generic risperidone by the end of 2008, followed by generic versions of all currently marketed schizophrenia drugs from 2011 onwards.
The increasing uptake of long-acting injectable (depot) atypical antipsychotics is expected to partially alleviate the branded schizophrenia sales decline. Positive effects on patient compliance will stimulate sales of these formulations which are forecast to reach a combined value of $1.2 billion by 2013.
The schizophrenia late-stage pipeline lacks innovation. Sales of most oral investigational drugs will be limited by extensive generic competition across the 7MM. However, drugs with novel mechanism of action could prove commercially successful, demanding a price premium and offering alternative treatments for refractory patients.
Reasons to Purchase
*Understand the current schizophrenia market dynamics and how they are expected to evolve out to 2017.
*Benchmark key late-stage pipeline schizophrenia compounds against the current market leading brands.
*Understand unmet needs and opportunities in the schizophrenia market based on key opinion leader comments.
Schizophrenia is a chronic and severe mental health disorder affecting around 4.6 million schizophrenia sufferers across the seven major markets. Currently led by oral branded atypical antipsychotics, the schizophrenia market will undergo some big changes over the period 20082017. Prospective players can expect to face stiff competition from generic versions of all currently branded drugs.
Scope
*Analysis of key marketed brands and late-stage pipeline drugs.
*Schizophrenia-specific drug sales volume and value forecasts to 2017 in the US, Japan, and five major European markets.
*Identification of future market events that are expected to affect schizophrenia drug revenues.
*Analysis of patient potential, unmet needs and clinical trial design in schizophrenia.
Highlights
The schizophrenia market is anticipated to grow slowly until 2011 to reach $4.3 billion across the 7MM. Despite the launch of a few pipeline drugs, the market will decline thereafter owing to the widespread launch of generic risperidone by the end of 2008, followed by generic versions of all currently marketed schizophrenia drugs from 2011 onwards.
The increasing uptake of long-acting injectable (depot) atypical antipsychotics is expected to partially alleviate the branded schizophrenia sales decline. Positive effects on patient compliance will stimulate sales of these formulations which are forecast to reach a combined value of $1.2 billion by 2013.
The schizophrenia late-stage pipeline lacks innovation. Sales of most oral investigational drugs will be limited by extensive generic competition across the 7MM. However, drugs with novel mechanism of action could prove commercially successful, demanding a price premium and offering alternative treatments for refractory patients.
Reasons to Purchase
*Understand the current schizophrenia market dynamics and how they are expected to evolve out to 2017.
*Benchmark key late-stage pipeline schizophrenia compounds against the current market leading brands.
*Understand unmet needs and opportunities in the schizophrenia market based on key opinion leader comments.
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
